<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01681615</url>
  </required_header>
  <id_info>
    <org_study_id>ASA-ST-OS</org_study_id>
    <secondary_id>2012-000698-22</secondary_id>
    <nct_id>NCT01681615</nct_id>
  </id_info>
  <brief_title>Challenge Test for Acetylsalicylic Acid Hypersensitivity</brief_title>
  <official_title>Challenge Test for Acetylsalicylic Acid Hypersensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helse Stavanger HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to find new challenge test for Acetylsalicylic hypersensitivity /
      Aspirin hypersensitivity. The investigators suggest that this new test will be as efficient
      as the already established protocols in terms of sensitivity and specificity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypersensitivity to Acetylsalicylic Acid or Aspirin (and other NSAIDS) is a condition that
      affects up to 2,5% of the population. Most cases are seen in a complex of such
      hypersensitivity with chronic eosinophilic rhinosinusitis with nasal polyposis and asthma.
      Despite research in finding a reliable in-vitro-test for the condition, challenge tests are
      still considered gold standard. So far oral, nasal, inhalation and intravenous routes of
      administration has been described in literature.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inspiratory nasal flow measured by Rhinomanometry</measure>
    <time_frame>Within 45 min from challenge</time_frame>
    <description>Bilateral flow reduction &gt;40% considered positive test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expiratory nasal flow measured by Rhinomanometry</measure>
    <time_frame>Within 45 min from challenge</time_frame>
    <description>Bilateral expiratory flow reduction &gt;40% considered positive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>Within 45 min from challenge</time_frame>
    <description>Reduction in FEV1 &gt;20% is considered as positive test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Conjunctival symptoms</measure>
    <time_frame>Within 45 days from challenge</time_frame>
    <description>0=no symptoms, 1=limited redness and / or itching, 2=conjunctival redness and /or itching / swelling or bullae within 5 minutes from testing.
Value 1 and 2 is considered positive if unilateral.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal symptoms</measure>
    <time_frame>Within 45 minutes from challenge</time_frame>
    <description>Rhinorrhea, congestion and sneezing is considered as positive test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchial and laryngeal symptoms</measure>
    <time_frame>Within 45 minutes from challenge</time_frame>
    <description>Bronchospasm. tight chest, wheezing or laryngospasm is considered as positive test.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Other significant and relevant symptoms</measure>
    <time_frame>Within 45 days after challenge</time_frame>
    <description>Erythema in upper body or face, nausea or abdominal pain is considered as positive test.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Asthma Aspirin-sensitive</condition>
  <condition>ASA Intolerant Asthma</condition>
  <condition>Asthma, Aspirin-Induced</condition>
  <condition>Asthma, Nasal Polyps, and Aspirin Intolerance</condition>
  <arm_group>
    <arm_group_label>Acetylsalicylate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetylsalicylic Acid Eyedrops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>isotonic NaCl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Eyedrops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylate</intervention_name>
    <description>1-2 drops</description>
    <arm_group_label>Acetylsalicylate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic NaCl</intervention_name>
    <description>1 drop</description>
    <arm_group_label>isotonic NaCl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persons between 18 and 60 years of age

          -  Suspected Acetylsalicylic Acid Hypersensitivity

        Exclusion Criteria:

          -  History on anaphylactic shock after NSAIDS intake

          -  History on gastric ulcer after NSAIDS intake

          -  Patients previously gone through testing or desensitisation for Aspirin
             hypersensitivity

          -  Clinical unstable asthma or baseline FEV1&lt;70%

          -  Severe disease of the heart, digestive tract, liver or kidney

          -  Severe chronic urticaria

          -  Present conjunctivitis

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregor Bachmann-Harildstad, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University in Oslo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gregor Bachmann-Harlidstad, MD, PhD</last_name>
    <phone>0047 02900 (central)</phone>
    <email>Gregor.Bachmann-Harlidstad2@ahus.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jörg Törpel, MD</last_name>
    <phone>0047 05151 (central)</phone>
    <email>jörg.törpel@sus.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <state>Akershus</state>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gregor Bachmann-Harlidstad, MD, PhD</last_name>
      <phone>0047 02900 (central)</phone>
      <email>gregor.bachmann.harlidstad2@ahus.no</email>
    </contact>
    <contact_backup>
      <last_name>Mohammad Sohrabi, MD</last_name>
      <phone>0047 02900 (central)</phone>
      <email>mohammad.sohrabi@ahus.no</email>
    </contact_backup>
    <investigator>
      <last_name>Gregor Bachmann-Harildstad, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammad Sohrabi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <state>Rogaland</state>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anders Torp, MD</last_name>
      <phone>0047 05151 (central)</phone>
      <email>anders.torp@sus.no</email>
    </contact>
    <contact_backup>
      <last_name>Jörg Törpel, MD</last_name>
      <phone>0047 05151 (central)</phone>
      <email>jörg.törpel@sus.no</email>
    </contact_backup>
    <investigator>
      <last_name>Anders Torp, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jörg Törpel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol. 2001 Sep;87(3):177-80.</citation>
    <PMID>11570612</PMID>
  </reference>
  <reference>
    <citation>Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol. 1999 Aug;28(4):717-22.</citation>
    <PMID>10480701</PMID>
  </reference>
  <reference>
    <citation>Kasper L, Sladek K, Duplaga M, Bochenek G, Liebhart J, Gladysz U, Malolepszy J, Szczeklik A. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy. 2003 Oct;58(10):1064-6.</citation>
    <PMID>14510727</PMID>
  </reference>
  <reference>
    <citation>Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax. 2002 Jul;57(7):569-74.</citation>
    <PMID>12096197</PMID>
  </reference>
  <reference>
    <citation>Samter M, Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med. 1968 May;68(5):975-83.</citation>
    <PMID>5646829</PMID>
  </reference>
  <reference>
    <citation>Stevenson D SR, Zuraw BL. Sensitivity to aspirin and NSAIDs. Adkinson NJ YJ, Busse WW, et al., editor. Philadelphia: CV Mosby and Co.; 2003</citation>
  </reference>
  <reference>
    <citation>Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczyńska M, Picado C, Scadding G, Kowalski ML, Setkowicz M, Ring J, Brockow K, Bachert C, Wöhrl S, Dahlén B, Szczeklik A. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy. 2007 Oct;62(10):1111-8. Epub 2007 May 22. Review.</citation>
    <PMID>17521312</PMID>
  </reference>
  <reference>
    <citation>Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol. 2006 Oct;118(4):773-86; quiz 87-8. 9. Mastalerz L, Setkowicz M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol. 2004 Apr;113(4):771-5</citation>
  </reference>
  <reference>
    <citation>Setkowicz M, Mastalerz L, Podolec-Rubis M, Sanak M, Szczeklik A. Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years. J Allergy Clin Immunol. 2009 Jan;123(1):174-8. doi: 10.1016/j.jaci.2008.09.005. Epub 2008 Oct 8.</citation>
    <PMID>18842291</PMID>
  </reference>
  <reference>
    <citation>Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J. 1975 Jan 11;1(5949):67-9.</citation>
    <PMID>1109660</PMID>
  </reference>
  <reference>
    <citation>Wong JT, Nagy CS, Krinzman SJ, Maclean JA, Bloch KJ. Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol. 2000 May;105(5):997-1001.</citation>
    <PMID>10808182</PMID>
  </reference>
  <reference>
    <citation>Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003 Jan;111(1):180-6.</citation>
    <PMID>12532116</PMID>
  </reference>
  <reference>
    <citation>Rozsasi A, Polzehl D, Deutschle T, Smith E, Wiesmiller K, Riechelmann H, Keck T. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy. 2008 Sep;63(9):1228-34. doi: 10.1111/j.1398-9995.2008.01658.x.</citation>
    <PMID>18699939</PMID>
  </reference>
  <reference>
    <citation>Stevenson DD. Aspirin sensitivity and desensitization for asthma and sinusitis. Curr Allergy Asthma Rep. 2009 Mar;9(2):155-63. Review.</citation>
    <PMID>19210906</PMID>
  </reference>
  <reference>
    <citation>Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol. 1996 Oct;98(4):751-8.</citation>
    <PMID>8876550</PMID>
  </reference>
  <reference>
    <citation>Sweet JM, Stevenson DD, Simon RA, Mathison DA. Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol. 1990 Jan;85(1 Pt 1):59-65.</citation>
    <PMID>2299107</PMID>
  </reference>
  <reference>
    <citation>Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, Settipane RA, Simon RA, Wald J, Woessner KM; Aspirin Desensitization Joint Task Force. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol. 2007 Feb;98(2):172-4.</citation>
    <PMID>17304886</PMID>
  </reference>
  <reference>
    <citation>Romano A, Torres MJ, Castells M, Sanz ML, Blanca M. Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol. 2011 Mar;127(3 Suppl):S67-73. doi: 10.1016/j.jaci.2010.11.047.</citation>
    <PMID>21354502</PMID>
  </reference>
  <reference>
    <citation>Wismol P, Putivoranat P, Buranapraditkun S, Pinnobphun P, Ruxrungtham K, Klaewsongkram J. The values of nasal provocation test and basophil activation test in the different patterns of ASA/NSAID hypersensitivity. Allergol Immunopathol (Madr). 2012 May-Jun;40(3):156-63. doi: 10.1016/j.aller.2010.12.011. Epub 2011 Apr 13.</citation>
    <PMID>21492991</PMID>
  </reference>
  <reference>
    <citation>Alonso-Llamazares A, Martinez-Cócera C, Domínguez-Ortega J, Robledo-Echarren T, Cimarra-Alvarez M, Mesa del Castillo M. Nasal provocation test (NPT) with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma (AIA). Allergy. 2002 Jul;57(7):632-5.</citation>
    <PMID>12100305</PMID>
  </reference>
  <reference>
    <citation>Milewski M, Mastalerz L, Nizankowska E, Szczeklik A. Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma. J Allergy Clin Immunol. 1998 May;101(5):581-6.</citation>
    <PMID>9600492</PMID>
  </reference>
  <reference>
    <citation>Krane Kvenshagen B, Jacobsen M, Halvorsen R. Can conjunctival provocation test facilitate the diagnosis of food allergy in children? Allergol Immunopathol (Madr). 2010 Nov-Dec;38(6):321-6. doi: 10.1016/j.aller.2010.01.007. Epub 2010 Jun 4.</citation>
    <PMID>20605314</PMID>
  </reference>
  <reference>
    <citation>Kralinger MT, Hamasaki D, Kieselbach GF, Voigt M, Parel JM. Intravitreal acetylsalicylic acid in silicone oil: pharmacokinetics and evaluation of its safety by ERG and histology. Graefes Arch Clin Exp Ophthalmol. 2001 Mar;239(3):208-16.</citation>
    <PMID>11405070</PMID>
  </reference>
  <reference>
    <citation>Kralinger MT, Stolba U, Velikay M, Egger S, Binder S, Wedrich A, Haas A, Parel JM, Kieselbach GF. Safety and feasibility of a novel intravitreal tamponade using a silicone oil/acetyl-salicylic acid suspension for proliferative vitreoretinopathy: first results of the Austrian Clinical Multicenter Study. Graefes Arch Clin Exp Ophthalmol. 2010 Aug;248(8):1193-8. doi: 10.1007/s00417-010-1389-7. Epub 2010 Apr 28.</citation>
    <PMID>20424852</PMID>
  </reference>
  <reference>
    <citation>Voigt M, Kralinger M, Kieselbach G, Chapon P, Anagnoste S, Hayden B, Parel JM. Ocular aspirin distribution: a comparison of intravenous, topical, and coulomb-controlled iontophoresis administration. Invest Ophthalmol Vis Sci. 2002 Oct;43(10):3299-306.</citation>
    <PMID>12356838</PMID>
  </reference>
  <reference>
    <citation>Mastalerz L, Setkowicz M, Sanak M, Szczeklik A. Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol. 2004 Apr;113(4):771-5.</citation>
    <PMID>15100686</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2012</study_first_submitted>
  <study_first_submitted_qc>September 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2012</study_first_posted>
  <last_update_submitted>September 12, 2012</last_update_submitted>
  <last_update_submitted_qc>September 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Challenge test for Aspirin Hypersensitivity</keyword>
  <keyword>Challenge test for Acetylsalicylic Hypersensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
    <mesh_term>Asthma, Aspirin-Induced</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

